RxDoctor Payments Data

Sandeep Jewani, MD

Pulmonary Disease · Louisville, KYNPI 1245627546

Payments from drug & device makers

$5,247in general payments, 2019–2025

Across 149 payments — averaging $35.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$2K
  • Pinnacle Biologics, Inc$641
  • AstraZeneca$634
  • GSK$387
  • Pulmonx Corporation$251
  • Mylan Specialty L.p.$241
  • plus $1K from 18 others

What the payments were for

  • Travel & lodging$1,76734%
  • Food & beverage$3,38064%
  • Education$992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,247 in reported general payments places this provider in the 45th percentile of 226 pulmonary disease providers in Kentucky.

See all pulmonary disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$216,563
Medicare patients
634
Services billed
2,460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter181$158,074
Breztri AerosphereBudesonide/Glycopyr/Formoterol36$24,395
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr32$19,969
Breo ElliptaFluticasone/Vilanterol21$13,903
Spiriva RespimatTiotropium Bromide19$13,766
Stiolto RespimatTiotropium Br/Olodaterol Hcl24$11,100
Bevespi AerosphereGlycopyrrolate/Formoterol Fum12$5,094
Albuterol Sulfate HfaAlbuterol Sulfate175$3,731
Ventolin HfaAlbuterol Sulfate37$2,140
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$2,127
BreynaBudesonide/Formoterol Fumarate12$809
Pantoprazole Sodium32$446
Montelukast Sodium46$251
Azithromycin23$204
Prednisone48$204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$387$191,946234 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere$634$29,48948 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$126$24,86743 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 226 pulmonary disease providers in Kentucky.

Other pulmonary disease in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →